添加电针到标准三重抗治疗对化疗诱导的恶心和吐的影响:一项随机对照临床试验
Guoshuang Shen1, Dengfeng Ren1, Fuxing Zhao1
1Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, China.
概括
在标准的抗治疗中添加电针显著改善了乳腺癌患者的化疗诱导的恶心和吐 (CINV) 的治疗. 这种方法在化疗期间提供了更好的完整保护和症状控制.
科学领域:
- 在瘤学瘤学.
- 综合医学是一个整体医学.
- 临床药理学 临床药理学
背景情况:
- 化疗引起的恶心和吐 (CINV) 是接受癌症治疗的患者面临的重大挑战.
- 标准的三重抗治疗提供了基线,但可能不会完全缓解所有患者的症状.
- 探索电等辅助疗法对于改善化疗期间患者的生活质量至关重要.
研究的目的:
- 评估将电针纳入标准三重抗治疗中用于管理CINV的有效性.
- 确定电是否可以提高完全保护率,并减少乳腺癌患者接受高排泄性化疗 (HEC) 的恶心和吐严重程度.
主要方法:
- 一个随机的,盲目的,假的受控试验,涉及239名乳腺癌患者在六家医院接受HEC.
- 参与者接受了真正的电或假电,并接受了标准的三重抗治疗.
- 主要结局是患者在化疗后120小时内实现完全保护 (没有吐,没有救援治疗,没有明显的恶心) 的比例.
主要成果:
- 与假电相比,真正的电显著提高了完全保护率 (52.9%对34.5%,P = .004).
- 真正的电治疗组也显示了总体症状控制的改善,恶心严重程度降低 (VAS得分),并且没有恶心的比率更高.
- 虽然在急性阶段没有发现显著的差异,但在CINV的延迟阶段,电显示出更高的疗效.
结论:
- 真正的电,当添加到标准的三重抗治疗时,显著改善了接受HEC的乳腺癌患者的CINV管理.
- 这种综合性方法提供了一种有前途的策略,可以加强化学疗法期间的抗控制和患者福祉.
- 进一步的研究可能会探索最佳的电针方案及其在不同患者群体和化疗方案中的应用.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
204
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
204
01:30Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
01:22Pathophysiology of Vomiting
342
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
342